Regeneron Pharmaceuticals (NQ:REGN)

735.20 +0.39 (+0.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

66 67 Next >

Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗

December 16, 2025

Via MarketBeat

2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

December 15, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

2 Reasons to Buy Regeneron Stock Like There's No Tomorrow ↗

December 13, 2025

Look beyond the healthcare company's recent setbacks.

Via The Motley Fool

3 Low-Volatility Stocks We’re Skeptical Of

December 10, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

December 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

3 Cash-Producing Stocks We Find Risky

December 03, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny

December 03, 2025

New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN)...

Via MarketMinute

Topics Intellectual Property

Exploring the top movers within the S&P500 index during today's session. ↗

December 01, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗

December 01, 2025

Via MarketBeat

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

December 01, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

The comeback may have begun.

Via The Motley Fool

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

November 25, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month ↗

November 24, 2025

Markets are dipping lower this month, but positive news from the FDA has this biotech stock ripping higher.

Via The Motley Fool

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy World Trade

3 Nasdaq 100 Stocks We Keep Off Our Radar

November 21, 2025

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

November 20, 2025

Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.

Via Chartmill

Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗

November 20, 2025

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lift Wall Street on Thursday.

Via Benzinga

What's going on in today's session: S&P500 movers ↗

November 20, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss ↗

November 20, 2025

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.

Via Benzinga

Which S&P500 stocks are moving before the opening bell on Thursday? ↗

November 20, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.

Via Chartmill

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

November 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Wall Street Braces for Impact as Delayed Jobs Report Emerges from Data Blackout

November 19, 2025

New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

November 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Pharmaceuticals (NASDAQ:REGN) Screens as a Compelling Value Investment ↗

November 18, 2025

Regeneron (REGN) appears undervalued with a low P/E ratio, strong profitability, and a rock-solid financial health profile. A compelling value stock.

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

November 17, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

1 S&P 500 Stock with Exciting Potential and 2 We Question

November 16, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Via Benzinga

Topics Artificial Intelligence

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.